Cholesterol synthesis disruption combined with a molecule-targeted drug is a promising metabolic therapy for EGFR mutant non-small cell lung cancer

BACKGROUND: Acquired resistance is a challenge for epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer. Here, we propose a novel treatment strategy based on recent lipid metabolism work. METHODS: We applied a variety of experimental methods such as immunoblotting, MTT, si-RNA,...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Youli, Yang, Yunpeng, Peng, Peijian, Zhan, Jianhua, Wang, Zhihui, Zhu, Zhiquan, Zhang, Zhonghan, Liu, Lin, Fang, Wenfeng, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867776/
https://www.ncbi.nlm.nih.gov/pubmed/33569299
http://dx.doi.org/10.21037/tlcr-20-812

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867776/
https://www.ncbi.nlm.nih.gov/pubmed/33569299
http://dx.doi.org/10.21037/tlcr-20-812

Ejemplares similares